Antiplatelet medications in the secondary prevention of ischemic stroke
- James D. Fleck MD
- … show all 1 hide
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
It is difficult to make general statements regarding choices in the medical management of patients with IS given its multiple mechanisms and individual patient variations. It is exceedingly important to manage all vascular risk factors in each patient, especially hypertension. Managing risk factors is as important as, or perhaps more important than, deciding on a prevention medication. Based on the previous discussion, I present my recommendations for antiplatelet secondary prevention of noncardioembolic IS.
Fields WS, Lemak NA, Frankowski RF, Hardy RJ: Controlled trial of aspirin in cerebral ischemia. Stroke 1977, 8:301–314.PubMed
The Canadian Cooperative Study Group: A randomized trial of aspirin and sulfinpyrazone in threatened stroke. The Canadian Cooperative Study Group. N Engl J Med 1978, 299:53–59.CrossRef
CAPRIE Steering Committee: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996, 348:1329–1339.CrossRef
Bousser MG, Eschwege E, Haguenau M, et al.: “AICLA” controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke 1983, 14:5–14.PubMed
CHARISMA: http://www.clinicaltrials.gov/ct/show/NCT00050817. Accessed August 15, 2004.
PRoFESS: http://www.profess-study.com. Accessed August 15, 2004.
SPS3: http://www.clinicaltrials.gov/ct/show/NCT00059306. Accessed August 15, 2004.
- Antiplatelet medications in the secondary prevention of ischemic stroke
Current Neurology and Neuroscience Reports
Volume 5, Issue 1 , pp 1-3
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links
- Author Affiliations
- 1. Department of Neurology, Indiana University School of Medicine, CL 291, 541 Clinical Drive, 46202, Indianapolis, IN, USA